We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

Virpax Pharmaceuticals Inc

Company price
0.002 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
51
Market Cap
1.53M

Momentum Score

…

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.02
High
52 Week Price Range
0.63
Low
11.77
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Virpax Pharmaceuticals Inc, traded as VRPX on the Pink Sheets, has limited recent public disclosures and a sparse operating history, so available sources provide little detail about its operations or product portfolio. Because public information is limited, long-term growth drivers would depend on successful clinical development, regulatory approvals or licensing and commercialization outcomes, which may appeal to investors seeking speculative small‑cap pharmaceutical exposure.

Material risks include limited transparency and liquidity, high execution and financing risk common to microcap biopharma issuers, potential dilution, and regulatory or clinical failure.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.37
ROE
-241.52%
Net Debt
-9.14M
ROCE
-1129.34%
Diluted EPS TTM
-14.42

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -21.65M -12.06M -4.34M -3.31M -2.64M
Net income -21.46M -12.15M -4.49M -3.43M -2.64M
Selling general administrative 11.08M 7.19M 2.90M 2.56M 1.48M
Ebit -21.85M -12.03M -4.20M -3.18M -2.63M
Ebitda -21.65M -11.96M -4.19M -3.18M -2.63M
Depreciation and amortization 0.19M 0.06M 0.00M - -
Operating income -21.85M -12.03M -4.20M -3.18M -2.63M
Other operating expenses 21.85M 12.03M 4.20M 3.18M 2.63M
Interest expense -0.19M 0.09M 0.15M 0.12M 0.01M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income 0.00M -0.09M -0.15M -0.12M -0.01M
Income tax expense -0.19M 0.09M 0.15M 0.12M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 21.85M 12.03M 4.20M 3.18M 2.63M
Total other income expense net 0.19M -0.03M -0.14M -0.12M -0.01M
Net income from continuing ops -21.65M -12.06M -4.34M -3.31M -2.64M
Net income applicable to common shares - -12.06M -4.34M -3.31M -2.64M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 9.63M 19.67M 39.57M 0.47M 0.05M
Other current assets 0.49M 0.68M 2.73M 0.00M 0.00M
Total liab 7.69M 3.09M 2.09M 4.68M 2.78M
Total stockholder equity 1.93M 16.58M 37.48M -4.22M -2.73M
Deferred long term liab - - - 0.39M -
Other current liab 7.69M 3.09M 2.09M 3.12M 1.51M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -59.54M -44.35M -22.70M -10.65M -6.31M
Other assets - - - 0.39M -
Cash 9.14M 19.00M 36.84M 0.05M 0.04M
Total current liabilities 7.69M 3.09M 2.09M 3.66M 2.78M
Net debt -9.14M -19.00M -36.84M 1.51M 1.22M
Short term debt - - - 0.54M 1.26M
Short long term debt - - - 0.54M 1.26M
Short long term debt total - - - 1.57M 1.26M
Other stockholder equity 61.48M 60.93M 60.19M 6.43M 3.58M
Total current assets 9.63M 19.67M 39.57M 0.07M 0.05M
Net tangible assets - - 37.48M -4.22M -2.73M
Net receivables - - - 0.00M 0.00M
Long term debt - - - 1.02M -
Inventory - - - - 0.00M
Accounts payable 0.00M 0.00M 0.00M 3.12M 0.00M
Accumulated other comprehensive income 0.00M - - - -
Common stock total equity - - - 0.00M 0.00M
Non currrent assets other - - - 0.39M -
Non current assets total 0.00M 0.00M 0.00M 0.39M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Change to liabilities - -0.69M 1.34M 0.92M 0.45M
Net borrowings - -1.50M 0.07M 0.50M 0.55M
Total cash from financing activities 0.00M 51.33M 1.40M 1.12M 1.67M
Change to operating activities - -2.71M -0.01M 0.01M -0.01M
Net income -21.65M -12.06M -4.34M -3.31M -2.64M
Change in cash -17.85M 36.79M 0.01M -0.01M -0.12M
Begin period cash flow 36.84M 0.05M 0.04M 0.05M 0.17M
End period cash flow 19.00M 36.84M 0.05M 0.04M 0.05M
Total cash from operating activities -17.85M -14.54M -1.38M -1.13M -1.80M
Issuance of capital stock 0.00M 58.02M 1.38M 0.62M 1.12M
Other cashflows from financing activities - -5.09M 0.02M 0.50M 0.55M
Change to netincome - 0.91M 1.63M 1.24M 0.40M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 3.06M -3.40M 1.33M 0.93M 0.44M
Stock based compensation 0.75M 0.97M 1.47M 0.68M 0.38M
Other non cash items - -0.06M 0.15M 0.56M 0.01M
Free cash flow -17.85M -14.54M -1.38M -1.13M -1.80M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
VRPX
Virpax Pharmaceuticals Inc
-
-%
0.00 - - - 2.15 0.29
NVO
Novo Nordisk A/S
-0.54
1.32%
40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-2.37
0.43%
544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-2.77
0.29%
956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

1055 Westlakes Drive, Berwyn, PA, United States, 19312

610 727 4597

7

Name Title Year Born
Mr. Anthony P. Mack M.B.A. Chairman & CEO 1962
Mr. Christopher M. Chipman CPA, CPA CFO & Corp. Sec. 1972
Dr. Jeffrey A. Gudin M.D. Exec. VP, Chief Medical Officer & Director 1965
Mr. Gerald W. Bruce Exec. VP of Commercial Operations & Director 1957
Dr. Sheila A. Mathias J.D., M.B.A., Ph.D. Chief Scientific Officer NA
Shana Panzarella Chief of Staff NA
Mr. Gerald W. Bruce CEO & Director 1957
Dr. Sheila A. Mathias J.D., M.B.A., Ph.D. Chief Scientific Officer 1968
Dr. Jeffrey A. Gudin M.D. Executive VP, Chief Medical Officer & Director 1966
Mr. Vinay Shah A.C.A., M.B.A. CFO, Principal Financial Officer, Principal Accounting Officer & Corporate Secretary 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…